在急性髓性白血病中CAR-T细胞疗法的突破:来自ASH 2024的更新
Haixiao Zhang1,2, Hong-Hu Zhu3,4
1Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, 100020, China.
Experimental hematology & oncology
|April 11, 2025
概括
化学抗原受体 (CAR) T细胞疗法在急性髓性白血病 (AML) 中显示出前景. 最近的进展集中在新的目标和工程策略上,以克服治疗这种具有挑战性的血液癌症的挑战.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
背景情况:
- 化学抗原受体 (CAR) T细胞疗法已经改变了淋巴细胞恶性瘤治疗.
- 它在急性髓性白血病 (AML) 的应用面临重大障碍,包括抗原选择,骨髓抑制和免疫抑制瘤微环境.
研究的目的:
- 总结了在2024年ASH会议上提出的针对AML的CAR T细胞疗法的最新进展.
- 提供关于提高CAR T细胞在AML治疗中的有效性和安全性的新策略的见解.
主要方法:
- 在2024年ASH会议上提出的临床试验和临床前研究的审查.
- 分析新兴的CAR T细胞工程策略和AML的向抗原.
主要成果:
- 临床试验正在探索针对AML的CD33,CD123,CLL1,CD19和IL1RAP等目标.
- 新型工程方法包括双重准CAR,抑制CAR设计和基因组编辑以改善结果.
结论:
- 针对AML的CAR T细胞疗法正在迅速发展,具有有前途的新目标和创新的工程技术.
- 这些进展旨在克服现有的局限性,并提高AML患者的治疗疗效.
更多相关视频
08:46A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
53.1K
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.2K
相关概念视频
01:27Tumor Immunotherapy
406
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
406
01:22Bone Marrow Sampling and Transplants
263
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
263